USE OF DE-NOVO mTOR INHIBITORS IN HYPERSENSITZED KIDNEY TRASPLANT RECIPIENTS: EXPERIENCE FROM CLINICAL PRACTICE.
暂无分享,去创建一个
J. Rovira | F. Diekmann | E. Montagud-Marrahi | I. Revuelta | D. Cucchiari | G. Piñeiro | P. Ventura-Aguiar | J. Martorell. | M. Solé | J. Campistol | F. Oppenheimer | J. Torregrosa | J. Ríos | J. Ugalde-Altamirano | N. Esforzado | M. Ricart | E. de Sousa-Amorim | F. Cofan | F. J. Centellas-Pérez | Alícia Molina-Andújar | Gaston J. Piñeiro | Enrique Montagud-Marrahi
[1] S. Chadban,et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. , 2018, Journal of the American Society of Nephrology : JASN.
[2] J. Rovira,et al. Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection , 2018, Transplantation.
[3] F. Diekmann,et al. Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome , 2018, Kidney international reports.
[4] M. Stegall,et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] J. Pascual,et al. Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities. , 2017, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[6] F. Luan,et al. Efficacy and Safety of Everolimus Plus Low‐Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard‐Dose Tacrolimus in De Novo Renal Transplant Recipients: 12‐Month Data , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] OPTN/SRTR 2015 Annual Data Report: Preface , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] J. Rovira,et al. Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro. , 2016, Transplantation proceedings.
[9] Mary E. Ziegler,et al. Everolimus Inhibits Anti‐HLA I Antibody‐Mediated Endothelial Cell Signaling, Migration and Proliferation More Potently Than Sirolimus , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] S. Takahara,et al. Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results , 2013, Transplantation research.
[11] R. Walker,et al. Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation , 2013, Transplantation.
[12] K. Budde,et al. Combined standard and novel immunosuppressive substances affect B-lymphocyte function. , 2013, International immunopharmacology.
[13] N. Unterwalder,et al. Effects of sotrastaurin, mycophenolic acid and everolimus on human B‐lymphocyte function and activation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.
[14] M. Christiaans,et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.
[15] E. Wang,et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[16] A. Matas,et al. Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] L. Kucirka,et al. Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.
[18] Sandra K. Wittmann,et al. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] D. Roelen,et al. Effects of Immunosuppressive Drugs On Purified Human B Cells: Evidence Supporting the Use of MMF and Rapamycin , 2008, Transplantation.
[20] W. Meyers,et al. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. , 2008, Transplant immunology.
[21] S. Jordan,et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.
[22] L. Shaw,et al. Multicenter, Randomized Study of the Use of Everolimus With Tacrolimus After Renal Transplantation Demonstrates its Effectiveness , 2008, Transplantation.
[23] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[24] M. Franco,et al. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus‐based immunosuppressive regimen , 2007, Clinical transplantation.
[25] G. Opelz,et al. Disassociation Between Risk of Graft Loss and Risk of Non-Hodgkin Lymphoma With Induction Agents in Renal Transplant Recipients , 2006, Transplantation.
[26] D. Abramowicz,et al. Tacrolimus Combined with Two Different Dosages of Sirolimus in Kidney Transplantation: Results of a Multicenter Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] S. Jensik,et al. A Prospective, Randomized Trial of Tacrolimus in Combination with Sirolimus or Mycophenolate Mofetil in Kidney Transplantation: Results at 1 Year , 2005, Transplantation.
[28] S. Mulgaonkar,et al. Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study , 2005, Transplantation.
[29] Raimund Margreiter,et al. Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients , 2004, Transplantation.
[30] J. Gaynor,et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year , 2004, Transplantation.
[31] O. Toupance,et al. Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF‐containing Triple Therapy , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[32] D. Jelinek,et al. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. , 1994, Cellular immunology.